PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs AMGN |
|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 0.12 | 17.8 | 149.5% | -99% |
| LLY | Eli Lilly and Company | 1.55 | 42.6 | 27.5% | -83% |
| MRK | Merck & Co., Inc. | 1.74 | 36.8 | 21.2% | -81% |
| BMY | Bristol-Myers Squibb Company | 3.37 | 17.6 | 5.2% | -62% |
| PFE | Pfizer Inc. | 12.24 | 18.8 | 1.5% | +37% |